KNSA Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $12.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 4,600 | $80.30 | $369.4K | 29,062 −13.7% of holding | |
| Cole G Bradley | Director | Sell | 3,673 | $81.43 | $299.1K | 11,672 −23.9% of holding | |
| Paolini John F. 2 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 58,424 | $53.71 | $3.1M | 86,720 −40.3% of holding | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 48,565 | $54.02 | $2.6M | None left | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 2,141 | $54.01 | $115.6K | None left | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 22,544 | $54.01 | $1.2M | None left | |
| Patel Sanj K 4 fills | CHAIRMAN & CEO | Sell 10b5-1 | 483,654 | $51.86 | $25.1M | 409,019 −54.2% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 13,099 | $50.10 | $656.3K | 12,546 −51.1% of holding | |
| Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 6,625 | $46.69 | $309.3K | 27,418 −19.5% of holding | |
| Moat Ross | CHIEF OPERATING OFFICER | Sell 10b5-1 | 1,703 | $46.69 | $79.5K | 12,029 −12.4% of holding | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 7,278 | $50.01 | $364.0K | None left | |
| Quart Barry D | Director | Sell 10b5-1 | 6,901 | $50.00 | $345.1K | 12,546 −35.5% of holding | |
| Moat Ross | CHIEF OPERATING OFFICER | Sell 10b5-1 | 2,367 | $48.58 | $115.0K | 12,029 −16.4% of holding | |
| Ragosa Mark 2 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 36,722 | $45.92 | $1.7M | 30,827 −54.4% of holding | |
| Paolini John F. 3 fills | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 40,000 | $44.82 | $1.8M | 89,261 −30.9% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 2,690 | $45.00 | $121.1K | 12,546 −17.7% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 110 | $45.00 | $5.0K | 12,546 −0.9% of holding | |
| Ragosa Mark 2 fills | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 17,845 | $43.28 | $772.3K | 20,817 −46.2% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 2,602 | $45.02 | $117.1K | 12,546 −17.2% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 12,528 | $45.27 | $567.1K | 12,546 −50% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 830 | $45.00 | $37.4K | 12,546 −6.2% of holding | |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 12,000 | $41.89 | $502.7K | 19,086 −38.6% of holding | |
| Quart Barry D | Director | Sell 10b5-1 | 20,129 | $41.51 | $835.6K | 12,546 −61.6% of holding | |
| Tessari Eben | CHIEF OPERATING OFFICER | Sell 10b5-1 | 12,048 | $41.56 | $500.7K | 16,666 −42% of holding | |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 42,841 | $41.49 | $1.8M | 31,086 −58% of holding | |
| Tessari Eben | CHIEF OPERATING OFFICER | Sell 10b5-1 | 200 | $42.89 | $8.6K | 22,714 −0.9% of holding | |
| Tessari Eben 2 fills | CHIEF OPERATING OFFICER | Sell 10b5-1 | 12,470 | $41.24 | $514.2K | 34,539 −26.5% of holding | |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 19,900 | $40.94 | $814.7K | 31,086 −39% of holding | |
| Paolini John F. | CHIEF MEDICAL OFFICER | Sell 10b5-1 | 82,542 | $37.14 | $3.1M | 61,324 −57.4% of holding | |
| Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell 10b5-1 | 100 | $41.00 | $4.1K | 31,086 −0.3% of holding | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 97,390 | $38.83 | $3.8M | 111,794 −46.6% of holding | |
| Patel Sanj K | CHAIRMAN & CEO | Sell 10b5-1 | 39,331 | $38.77 | $1.5M | 111,794 −26% of holding | |
| Patel Sanj K 2 fills | CHAIRMAN & CEO | Sell 10b5-1 | 121,248 | $38.90 | $4.7M | 134,108 −47.5% of holding | |
| Megna Michael R 2 fills | CHIEF ACCOUNTING OFFICER | Sell 10b5-1 | 50,490 | $38.87 | $2.0M | 40,281 −55.6% of holding | |
| Tessari Eben 2 fills | CHIEF OPERATING OFFICER | Sell 10b5-1 | 12,368 | $37.67 | $465.8K | 29,237 −29.7% of holding | |
| Tessari Eben | CHIEF OPERATING OFFICER | Sell 10b5-1 | 42,000 | $38.33 | $1.6M | 34,552 −54.9% of holding | |
| Tessari Eben 2 fills | CHIEF OPERATING OFFICER | Sell 10b5-1 | 16,400 | $36.46 | $598.0K | 34,908 −32% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.